Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 110 people, planned
- Started
- 1 Oct 2026
- Expected to end
- Aug 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- [11C]OMAR
- Record updated
- 2 October 2026
Who can take part
- Age
- 25 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- All
- Normal screening bloodwork
- Adequate arterial access for placement of an arterial line and blood sampling per study protocol; OUD Participants:
- Diagnosis of opioid use disorder (OUD) according to DSM-5 criteria
- Actively seeking treatment for OUD
- Willingness to initiate opioid agonist therapy (OAT) with buprenorphine; Healthy Controls:
- Good general physical health
- No current or past diagnosis of any psychiatric or substance use disorders
Who cannot take part
- Prior participation in research studies within the past year that would result in cumulative radiation exposure exceeding annual limits
- Previous enrollment in the main study; Healthy Controls:
- Any current major medical condition that, in the opinion of the Principal Investigator, poses a risk for PET procedures
- History of neurological conditions, including stroke or seizure disorders
- Current or past diagnosis of a serious psychiatric disorder
- Current diagnosis of any substance use disorder other than nicotine or opioids
- Current or past diagnosis of any psychiatric disorder
- Current diagnosis of any substance use disorder (excluding nicotine)
- All
- Presence of ferromagnetic metal in the body, pacemaker, or other contraindications to MRI
- Positive pregnancy test or current lactation
- Hematocrit values lower than 30; OUD Participants
- Use of any substances within the past 30 days
- Current use of SSRIs or benzodiazepines or use within the past 30 days
- Use of any substances within the past 30 days
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Opioid use disorder or oat
This trial is currently available in United States.
- Connecticut Mental Health Center, Clinical Neuroscience Research UnitNew Haven, United StatesContact: Abigail DeweyTaking people
About the trial
What the trial wants to find out
The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.
The 2 groups in the trial
- Healthy VolunteersOther group
Healthy volunteers with no current or past major medical or psychiatric history
Treatment: [11C]OMAR
- Opioid Use Disorder in Opioid Agonist Therapy (OAT)Other group
Patients diagnosed with opioid use disorder during the early phase of opioid agonist therapy
Treatment: [11C]OMAR
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07800520, who can take part
- Record updated
- 2 October 2026